Alterations in striatal dopamine catabolism precede loss of substantia nigra neurons in a mouse model of juvenile neuronal ceroid lipofuscinosis

Brain Research

Volumn 1162, Issue 1, 2007, Pages 98-112

  Weimer, Jill M ^a   Benedict, Jared W ^a   Elshatory, Yasser M ^a   Short, Douglas W ^a   Ramirez Montealegre, Denia ^a   Ryan, Deborah A ^a   Alexander, Noreen A ^b   Federoff, Howard J ^a   Cooper, Jonathan D ^b   Pearce, David A ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Batten disease; Catechol O methyltransferase; CLN3; Dopamine; Oxidative stress

Indexed keywords

CATECHOL METHYLTRANSFERASE; DOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CLN3 GENE; COGNITIVE DEFECT; CONTROLLED STUDY; DETERIORATION; DISEASE MODEL; DOPAMINE RELEASE; GAIT DISORDER; GENE; GENE MUTATION; HALLUCINATION; LIPOFUSCINOSIS; MOUSE; MYOCLONUS; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SEIZURE; SUBSTANTIA NIGRA;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; CATECHOL O-METHYLTRANSFERASE; CELL DEATH; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; GENE EXPRESSION REGULATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; MOLECULAR CHAPERONES; MOTOR ACTIVITY; MOTOR SKILLS; NEURONAL CEROID-LIPOFUSCINOSES; NEURONS; SUBSTANTIA NIGRA;

MUS;

EID: 34447634680     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.05.018     Document Type: Article

References (51)

1. Aberg L., Liewendahl K., Nikkinen P., Autti T., Rinne J.O., and Santavuori P. Decreased striatal dopamine transporter density in JNCL patients with parkinsonian symptoms. Neurology 54 (2000) 1069-1074
2. Aberg L.E., Rinne J.O., Rajantie I., and Santavuori P. A favorable response to antiparkinsonian treatment in juvenile neuronal ceroid lipofuscinosis. Neurology 56 (2001) 1236-1239
3. Axelrod J., and Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem. 233 (1958) 702-705
4. Barisic N., Logan P., Pikija S., Skarpa D., and Blau N. R208X mutation in CLN2 gene associated with reduced cerebrospinal fluid pterins in a girl with classic late infantile neuronal ceroid lipofuscinosis. Croat. Med. J. 44 (2003) 489-493
5. Benedict, J.W., Sommers, C.A., Pearce, D.A., in press. Progressive oxidative damage in the CNS of a murine model of juvenile Batten disease. Journal of Neuroscience Research.
6. Bible E., Gupta P., Hofmann S.L., and Cooper J.D. Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 16 (2004) 346-359
7. Boudikova B., Szumlanski C., Maidak B., and Weinshilboum R. Human liver catechol-O-methyltransferase pharmacogenetics. Clin. Pharmacol. Ther. 48 (1990) 381-389
8. Brooks A.I., Chattopadhyay S., Mitchison H.M., Nussbaum R.L., and Pearce D.A. Functional categorization of gene expression changes in the cerebellum of a Cln3-knockout mouse model for Batten disease. Mol. Genet. Metab. 78 (2003) 17-30
9. Dalle-Donne I., Giustarini D., Colombo R., Rossi R., and Milzani A. Protein carbonylation in human diseases. Trends Mol. Med. 9 (2003) 169-176
10. Dalle-Donne I., Rossi R., Giustarini D., Milzani A., and Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin. Chim. Acta 329 (2003) 23-38
11. Ellingson T., Duddempudi S., Greenberg B.D., Hooper D., and Eisenhofer G. Determination of differential activities of soluble and membrane-bound catechol-O-methyltransferase in tissues and erythrocytes. J. Chromatogr., B, Biomed. Sci. Appl. 729 (1999) 347-353
12. Elshatory Y., Brooks A.I., Chattopadhyay S., Curran T.M., Gupta P., Ramalingam V., Hofmann S.L., and Pearce D.A. Early changes in gene expression in two models of Batten disease. FEBS Lett. 538 (2003) 207-212
13. Fan J.B., Zhang C.S., Gu N.F., Li X.W., Sun W.W., Wang H.Y., Feng G.Y., St Clair D., and He L. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis. Biol. Psychiatry 57 (2005) 139-144
14. Fossale E., Wolf P., Espinola J.A., Lubicz-Nawrocka T., Teed A.M., Gao H., Rigamonti D., Cattaneo E., MacDonald M.E., and Cotman S.L. Membrane trafficking and mitochondrial abnormalities precede subunit c deposition in a cerebellar cell model of juvenile neuronal ceroid lipofuscinosis. BMC Neurosci. 5 (2004) 57
15. Galderisi S., Maj M., Kirkpatrick B., Piccardi P., Mucci A., Invernizzi G., Rossi A., Pini S., Vita A., Cassano P., Stratta P., Severino G., and Del Zompo M. Catechol-O-Methyltransferase ValMet polymorphism in schizophrenia: associations with cognitive and motor impairment. Neuropsychobiology 52 (2005) 83-89
16. Glaser C.B., Yamin G., Uversky V.N., and Fink A.L. Methionine oxidation, alpha-synuclein and Parkinson's disease. Biochim. Biophys. Acta 1703 (2005) 157-169
17. Guldberg H.C., and Marsden C.A. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol. Rev. 27 (1975) 135-206
18. Gundersen H.J., and Jensen E.B. The efficiency of systematic stereology and its prediction. J. Microsc. 147 (1987) 229-263
19. Hofman I., Kohlschutter A., Santavuori P., Gottlob I., Goebel H.H., Lake B.D., Schutgens R.B.H., Greene N.D., Leung K.-Y., Mitchison H.M., Munroe P.B., and Taschner P.E. The Neuronal Ceroid Lipofuscinses (Batten Disease) (1999), IOS Press, Amsterdam, The Netherlands
20. Holton K.L., Loder M.K., and Melikian H.E. Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization. Nat. Neurosci. 8 (2005) 881-888
21. Horowitz A., Shifman S., Rivlin N., Pisante A., and Darvasi A. A survey of the 22q11 microdeletion in a large cohort of schizophrenia patients. Schizophr. Res. 73 (2005) 263-267
22. Hsu M., Srinivas B., Kumar J., Subramanian R., and Andersen J. Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease. J. Neurochem. 92 (2005) 1091-1103
23. Kandel E.R., Schwartz J.H., and Jessell T.M. Principles of Neural Science. 4th Edition (2000), McGraw-Hill, New York, NY
24. Kielar C., Maddox L., Bible E., Pontikis C.C., Macauley S.L., Griffey M.A., Wong M., Sands M.S., and Cooper J.D. Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 25 (2007) 150-162
25. Koike H., Arguello P.A., Kvajo M., Karayiorgou M., and Gogos J.A. Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 3693-3697
26. Kovacs A.D., Weimer J.M., and Pearce D.A. Selectively increased sensitivity of cerebellar granule cells to AMPA receptor-mediated excitotoxicity in a mouse model of Batten disease. Neurobiol. Dis. 22 (2006) 575-585
27. Lin W.C., Tsai P.S., and Huang C.J. Catecholamines' enhancement of inducible nitric oxide synthase-induced nitric oxide biosynthesis involves CAT-1 and CAT-2A. Anesth. Analg. 101 (2005) 226-232 (table of contents)
28. Luiro K., Yliannala K., Ahtiainen L., Maunu H., Jarvela I., Kyttala A., and Jalanko A. Interconnections of CLN3, Hook1 and Rab proteins link Batten disease to defects in the endocytic pathway. Hum. Mol. Genet. 13 (2004) 3017-3027
29. Lundstrom K., Salminen M., Jalanko A., Savolainen R., and Ulmanen I. Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol. 10 (1991) 181-189
30. Malherbe P., Bertocci B., Caspers P., Zurcher G., and Da Prada M. Expression of functional membrane-bound and soluble catechol-O-methyltransferase in Escherichia coli and a mammalian cell line. J. Neurochem. 58 (1992) 1782-1789
31. Mitchison H.M., Bernard D.J., Greene N.D., Cooper J.D., Junaid M.A., Pullarkat R.K., de Vos N., Breuning M.H., Owens J.W., Mobley W.C., Gardiner R.M., Lake B.D., Taschner P.E., and Nussbaum R.L. Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten mouse model consortium. Neurobiol. Dis. 6 (1999) 321-334
32. Paxinos G., and Franklin K.B.J. The Mouse Brain in Stereological Coordinates. 2nd Edition (2001), Academic Press, San Diego, CA
33. Pihlavisto P., and Reenila I. Separation methods for catechol O-methyltransferase activity assay: physiological and pathophysiological relevance. J. Chromatogr., B Analyt. Technol. Biomed. Life Sci. 781 (2002) 359-372
34. -/- mouse model of juvenile neuronal ceroid lipofuscinosis is preceded by low level glial activation. Brain Res. 1023 (2004) 231-242
35. Pontikis C.C., Cotman S.L., Macdonald M.E., and Cooper J.D. Thalamocortical neuron loss and localized astrocytosis in the Cln3(Deltaex7/8) knock-in mouse model of Batten disease. Neurobiol. Dis. 20 (2005) 823-836
36. Porzgen P., Bonisch H., and Bruss M. Molecular cloning and organization of the coding region of the human norepinephrine transporter gene. Biochem. Biophys. Res. Commun. 215 (1995) 1145-1150
37. Ramirez-Montealegre D., and Pearce D.A. Defective lysosomal arginine transport in juvenile Batten disease. Hum. Mol. Genet. 14 (2005) 3759-3773
38. Reenila I., Tuomainen P., and Mannisto P.T. Improved assay of reaction products to quantitate catechol-O-methyltransferase activity by high-performance liquid chromatography with electrochemical detection. J. Chromatogr., B, Biomed. Appl. 663 (1995) 137-142
39. Reenila I., Tuomainen P., Soinila S., and Mannisto P.T. Increase of catechol-O-methyltransferase activity in rat brain microglia after intrastriatal infusion of fluorocitrate, a glial toxin. Neurosci. Lett. 230 (1997) 155-158
40. Rinne J.O., Ruottinen H.M., Nagren K., Aberg L.E., and Santavuori P. Positron emission tomography shows reduced striatal dopamine D1 but not D2 receptors in juvenile neuronal ceroid lipofuscinosis. Neuropediatrics 33 (2002) 138-141
41. Rivett A.J., Francis A., and Roth J.A. Localization of membrane-bound catechol-O-methyltransferase. J. Neurochem. 40 (1983) 1494-1496
42. Rivett A.J., Francis A., and Roth J.A. Distinct cellular localization of membrane-bound and soluble forms of catechol-O-methyltransferase in brain. J. Neurochem. 40 (1983) 215-219
43. Ruottinen H.M., Rinne J.O., Haaparanta M., Solin O., Bergman J., Oikonen V.J., Jarvela I., and Santavuori P. [18F]fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis. J. Neurol. Neurosurg. Psychiatry 62 (1997) 622-625
44. Salminen M., Lundstrom K., Tilgmann C., Savolainen R., Kalkkinen N., and Ulmanen I. Molecular cloning and characterization of rat liver catechol-O-methyltransferase. Gene 93 (1990) 241-247
45. Sappington R.M., Pearce D.A., and Calkins D.J. Optic nerve degeneration in a murine model of juvenile ceroid lipofuscinosis. Invest. Ophthalmol. Visual Sci. 44 (2003) 3725-3731
46. Seigel G.M., Lotery A., Kummer A., Bernard D.J., Greene N.D., Turmaine M., Derksen T., Nussbaum R.L., Davidson B., Wagner J., and Mitchison H.M. Retinal pathology and function in a Cln3 knockout mouse model of juvenile neuronal ceroid lipofuscinosis (Batten disease). Mol. Cell. Neurosci. 19 (2002) 515-527
47. Tai C.H., and Wu R.M. Catechol-O-methyltransferase and Parkinson's disease. Acta Med. Okayama 56 (2002) 1-6
48. Torres G.E., Gainetdinov R.R., and Caron M.G. Plasma membrane monoamine transporters: structure, regulation and function. Nat. Rev., Neurosci. 4 (2003) 13-25
49. Weimer J.M., Chattopadhyay S., Custer A.W., and Pearce D.A. Elevation of Hook1 in a disease model of Batten disease does not affect a novel interaction between Ankyrin G and Hook1. Biochem. Biophys. Res. Commun. 330 (2005) 1176-1181
50. Weinshilboum R., and Raymond F. Variations in catechol-O-methyltransferase activity in inbred strains of rats. Neuropharmacology 16 (1977) 703-706
51. Winqvist R., Lundstrom K., Salminen M., Laatikainen M., and Ulmanen I. The human catechol-O-methyltransferase (COMT) gene maps to band q11.2 of chromosome 22 and shows a frequent RFLP with BglI. Cytogenet. Cell Genet. 59 (1992) 253-257